Dr. Nolan Williams — Stanford psychiatrist and neurologist who directs the Brain Stimulation Lab, known for the rapid 'SAINT/SNT' transcranial magnetic stimulation protocol and clinical research on psychedelics for treatment-resistant depression and PTSD.
The gist
Andrew Huberman and Dr. Nolan Williams discuss why depression is the most disabling condition worldwide and how the field is moving past the 'chemical imbalance' model toward a circuit-based view of psychiatry. Williams describes his Stanford Neuromodulation Therapy (SNT/SAINT), which compresses six weeks of TMS into five days using spaced-learning theory and drives 60-90% of patients into remission. They then explore the neuroscience and clinical results of psychedelics including psilocybin and MDMA for depression and PTSD, plus ketamine, ibogaine, and ayahuasca. Williams shares anecdotes from treating special-operations veterans for moral injury and PTSD, and explains the converging brain-circuit mechanisms shared by TMS and psychedelics. Throughout, he stresses these substances are powerful, non-recreational tools that demand strict medical supervision.
Big reveals
- The American Heart Association added depression as the fourth major risk factor for coronary artery disease.
- Williams argues the serotonin 'chemical imbalance' theory of depression is wrong, since TMS works without adding any serotonin.
- Patients who remit early in a TMS week spontaneously report mindfulness-like 'present moment' experiences they'd only read about.
- About two-thirds of PTSD patients had a clinically significant improvement after MDMA-assisted therapy, lasting years for some.
- Williams is running what he calls the first full human neurobiological study of ibogaine, in special-operations veterans.
- Veterans report forgiving themselves for 'moral injury' after ibogaine, describing detached empathy and a 'life review'.
- A Brazilian study found ayahuasca-treated prisoners had a statistically significantly lower recidivism rate than controls.
- SNT delivers 7.5 months' worth of TMS dosing in 5 days, achieving 60-90% remission with some patients well for up to four years.
Things worth remembering
- TMS uses Faraday's law: a magnetic pulse induces an electrical current only in brain tissue, passing harmlessly through skull, scalp, and hair.
- Stimulating the dorsolateral prefrontal cortex traces a pathway to the vagus nerve and heart, letting researchers decelerate heart rate via the brain.
- SSRIs clearly work for a subset of people but not immediately, suggesting their benefit comes from brain plasticity rather than serotonin levels.
- A single ketamine infusion's antidepressant effect lasts only about a week and a half on average, requiring repeat dosing.
- Carhart-Harris and Nutt found psychedelics decrease overall brain activity while increasing global connectivity, the opposite of what they expected.
- Both SNT/TMS and psilocybin reduce connectivity between the subgenual anterior cingulate and the default mode network, a convergent mechanism.
- Ibogaine is an alkaloid extracted from the iboga tree root bark, native to Gabon, Africa.
- Ibogaine is the longest-acting psychedelic Williams knows of, lasting 24-36 hours and called '10 years of psychotherapy in a night'.
- Ayahuasca combines two of roughly 10,000-20,000 Amazonian plant species; a reversible MAO inhibitor lets oral DMT cross the blood-brain barrier.
- SNT applies spaced-learning theory, stimulating the brain every hour for 10 hours over 5 days (a 50-hour block, 90 minutes of actual stimulation).